Skip to main content

Table 4 Summary of AEs and SAEs (Safety Population)

From: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

 

Lumiracoxib 100 mg o.d. (n = 755)

Lumiracoxib 100 mg b.i.d. (n = 1,519)

Celecoxib 200 mg o.d. (n = 758)

Patients with AEs, n (%)

548 (72.6)

1078 (71.0)

526 (69.4)

Patients with SAEs, n (%)

41 (5.4)

72 (4.7)

48 (6.3)

   Fatal, n (%)†

2 (0.3)

7 (0.5)

1 (0.1)

Discontinuations due to AEs, n (%)

98 (13.0)

193 (12.7)

87 (11.5)

  1. o.d. = once daily; b.i.d. = twice daily; AEs = adverse events; SAEs = serious adverse events; †all deaths occurring before database lock are included.
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us